$384 Million is the total value of Integral Health Asset Management, LLC's 71 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MYOV | Exit | MYOVANT SCIENCES LTD | $0 | – | -25,000 | -100.0% | -0.11% | – |
| AMRN | Exit | AMARIN CORP PLCspons adr new | $0 | – | -200,000 | -100.0% | -0.19% | – |
| LXRX | Exit | LEXICON PHARMACEUTICALS INC | $0 | – | -200,000 | -100.0% | -0.22% | – |
| LYEL | Exit | LYELL IMMUNOPHARMA INC | $0 | – | -140,000 | -100.0% | -0.30% | – |
| IMGN | Exit | IMMUNOGEN INC | $0 | – | -250,000 | -100.0% | -0.51% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -130,000 | -100.0% | -0.58% | – |
| Exit | BRIDGEBIO PHARMA INCcall | $0 | – | -150,000 | -100.0% | -0.69% | – | |
| MASI | Exit | MASIMO CORP | $0 | – | -10,000 | -100.0% | -0.81% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -30,000 | -100.0% | -0.90% | – |
| ARWR | Exit | ARROWHEAD PHARMACEUTICALS IN | $0 | – | -50,000 | -100.0% | -0.92% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INC | $0 | – | -20,000 | -100.0% | -0.94% | – |
| GSK | Exit | GLAXOSMITHKLINE PLCsponsored adr | $0 | – | -100,000 | -100.0% | -1.22% | – |
| EW | Exit | EDWARDS LIFESCIENCES CORP | $0 | – | -45,000 | -100.0% | -1.61% | – |
| LH | Exit | LABORATORY CORP AMER HLDGS | $0 | – | -20,000 | -100.0% | -1.74% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -50,000 | -100.0% | -1.87% | – |
| FATE | Exit | FATE THERAPEUTICS INC | $0 | – | -130,000 | -100.0% | -2.10% | – |
| ABT | Exit | ABBOTT LABS | $0 | – | -70,000 | -100.0% | -2.73% | – |
| MCK | Exit | MCKESSON CORP | $0 | – | -55,000 | -100.0% | -3.78% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 15 | Q3 2023 | 4.7% |
| SAGE THERAPEUTICS INC | 15 | Q2 2023 | 5.0% |
| BIOMARIN PHARMACEUTICAL INC | 15 | Q2 2023 | 4.1% |
| ENVISTA HOLDINGS CORPORATION | 14 | Q3 2023 | 4.0% |
| AKERO THERAPEUTICS INC | 14 | Q3 2023 | 1.5% |
| REVVITY INC | 13 | Q3 2023 | 4.2% |
| BLUEPRINT MEDICINES CORP | 13 | Q3 2023 | 3.3% |
| PTC THERAPEUTICS INC | 13 | Q2 2023 | 1.7% |
| ELEVANCE HEALTH INC | 12 | Q3 2023 | 6.7% |
| NEVRO CORP | 12 | Q4 2022 | 4.5% |
View Integral Health Asset Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-03 |
| 13F-HR | 2022-05-12 |
| 13F-HR | 2022-02-02 |
| 13F-HR | 2021-11-12 |
View Integral Health Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.